'Corporate Reputation of Pharma in 2018 - the Perspective of French Patient Groups'
~ Contact: Alex Wyke ~ Tel: +44-(0)7960-855-019 ~ Email: report@patient-view.com
EMBARGO: London, November 12th, 2019 6AM GMT
ABOUT THIS REPORT AND SURVEY - In this, the last of our 2018 series of reports about the corporate reputation of the pharmaceutical industry, we look at the views of 53 patient groups headquartered in France. This the 1st edition of 'The Corporate Reputation of Pharma, 2018—from the Perspective of French Patient Groups'. For the sake of comparison,
these 2018 French results also contain French results calculated from the previous year, 2017.
- The 2018 results are drawn from a survey of patient groups worldwide, conducted November 2018-February 2019.
Profile of 2018's respondent French patient groups: - 53 French patient groups, of various specialties (7 of the patient groups focused on rare diseases.)
17% of the respondent patient groups had an international geographic remit; 67% were national groups; 12% regional (an area within France); and 4% were local patient groups. 57% of the French patient groups worked with one or more pharmaceutical companies.
Company analyses: The following 10 pharma companies were analysed by the 53 French patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation: Bayer I Boehringer Ingelheim
I GSK I Janssen I MSD (Merck Sharp & Dohme) I Novartis I Pierre Fabre I Pfizer I Roche I and Sanofi.
KEY FINDINGS ACROSS THE PHARMA INDUSTRY
2018’s 53 respondent French patient groups were marginally more positive about the corporate reputation of the pharma industry as a whole than patient groups in most of the rest of the world. 43% of the French patient groups stated that the industry had an “Excellent” or “Good” corporate reputation in 2018, compared with 41% of patient groups worldwide saying the same. However, the respondent French patient groups were significantly more negative than peer patient groups in other countries about the industry’s integrity, as well as about its ability to carry out a range of activities, including: provide high-quality
products; be innovative; and supply high-quality patient information.
Percentage of respondent patient groups stating that the corporate reputation of the pharmaceutical industry as a whole was “Excellent” or “Good”, 2018—French patient groups v. patient groups worldwide
How good or bad the pharmaceutical industry was in 2018 at carrying out specific activities—FRANCE v. global; percentage of respondent patient groups stating “Excellent” or “Good”
Maing high-quality products:
Providing high-quality information:
Feedback received from the respondent French patient groups points to several reasons behind these negative sentiments: The industry’s lack of consistency at corporate reputation. Association Française contre les Neuropathies Périphériques (AFNP) [French Association Against Peripheral Neuropathies] observed: “Résultats très fluctuants selon les industriels.” [“Results fluctuate wildly, depending on the manufacturer.”]
The industry’s lack of transparency. An autoimmune-disease patient group with a national remit commented: “Plus de transparence, que nous pourrions relater, contribuerait à un meilleur sentiment de confiance, tout ce qui est secret laisse supposer qu'il y a des choses à cacher.” [“More transparency that we could report on would contribute to a better sense of trust. Secrecy suggests the presence of things to hide.”]
A lack of good relations/communication. A national HIV/AIDS patient group thought that that companies limited their involvement with patient groups to recruiting patients for clinical trials, and it considered that they paid little attention to the issues faced by people on lifelong HIV treatments. And ...
A failure to keep patients informed. A national endometriosis patient group referred to its need for information on a range of issues, including: product safety; the limitations of drug treatments; and shortages in the supply of drugs. It stated: “Rupture de stock de médicaments dans toute la France.” [“Drugs are out of stock throughout France.”]
HOW DID COMPANIES PERFORM?
FACTORS TO CONSIDER: The relatively small number of French patient groups involved in the 2018 study means that fluctuations in company rankings, year on year, are likely. HOW CORPORATE REPUTATION IS MEASURED The overall corporate reputation of each company is assessed according to that company's performance (as judged by Asian patient groups) at 12 individual indicators of corporate reputation. The indicators [listed below] have been developed over the years by PatientView, drawing on recommendations from patient groups, health professionals, health regulators, and industry.
TOP-THREE COMPANIES IN FRANCE, 2018 - Pfizer was ranked overall 1st out of 10 companies for corporate reputation in 2018 by the 29 French patient groups claiming familiarity with it. These patient groups also ranked Pfizer first in 2018 for three of the 12 indicators of corporate reputation: ensuring patient safety; quality of patient-group relationships; and provision of services ‘beyond the pill’.
- Sanofi was ranked overall 2nd out of 10 companies for corporate reputation in 2018 by the 35 French patient groups claiming familiarity with it.
- Boehringer Ingelheim was ranked overall 3rd out of 10 companies for corporate reputation in 2018 by the 17 French patient groups claiming familiarity with it.
PatientView's 12 indicators used to assess pharma corporate reputation
- 1. Patient centricity.
- 2. Patient information.
- 3. Patient safety.
- 4. High-quality products.
- 5i. Transparency: pricing.
- 5ii. Transparency: clinical-trial data.
- 5iii. Transparency: funding of stakeholders.
- 6. Integrity.
- 7. Relationships with patient groups.
- 8. Providing services ‘beyond the pill’.
- 9i. Engaging patients in research.
- 9ii. Engaging patients in development.
The 10 companies ranked for corporate reputation—from the perspective of the 53 respondent French patient groups familiar with the company, 2018 v. 2017
For further information on the 2018 FRANCE Corporate-Reputation report, please use contact details at the top of this press release
|